KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CRISPR Therapeutics AG (CRSP) Equity Income (2016 - 2019)

CRISPR Therapeutics AG (CRSP) has disclosed Equity Income for 4 consecutive years, with -$3.4 million as the latest value for Q3 2019.

  • Quarterly Equity Income fell 238.93% to -$3.4 million in Q3 2019 from the year-ago period, while the trailing twelve-month figure was -$5.5 million through Dec 2019, down 27.88% year-over-year, with the annual reading at -$5.5 million for FY2019, 27.88% down from the prior year.
  • Equity Income hit -$3.4 million in Q3 2019 for CRISPR Therapeutics AG, down from -$1.0 million in the prior quarter.
  • In the past five years, Equity Income ranged from a high of -$359000.0 in Q3 2017 to a low of -$35.8 million in Q4 2016.
  • Historically, Equity Income has averaged -$3.7 million across 4 years, with a median of -$1.0 million in 2018.
  • Biggest five-year swings in Equity Income: skyrocketed 98.74% in 2017 and later plummeted 238.93% in 2019.
  • Year by year, Equity Income stood at -$35.8 million in 2016, then surged by 98.74% to -$453000.0 in 2017, then crashed by 124.94% to -$1.0 million in 2018, then crashed by 236.6% to -$3.4 million in 2019.
  • Business Quant data shows Equity Income for CRSP at -$3.4 million in Q3 2019, -$1.0 million in Q2 2019, and -$1.0 million in Q1 2019.